Literature DB >> 17544969

Pathologic assessment of non-alcoholic fatty liver disease.

Silvia Bondini1, David E Kleiner, Zachary D Goodman, Terry Gramlich, Zobair M Younossi.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) represents one of the most common forms of liver disease and is considered the hepatic manifestation of the metabolic syndrome. Within the NAFLD spectrum, simple steatosis is considered benign, whereas non-alcoholic steatohepatitis (NASH) may progress to cirrhosis. The distinction can be made only by liver biopsy. There is not complete agreement on criteria for diagnosis or the features used for grading and staging lesions. This article reviews some of the studies dealing with the histopathology of NAFLD, with attempts to develop a standardized pathologic scoring system for NASH.

Entities:  

Mesh:

Year:  2007        PMID: 17544969     DOI: 10.1016/j.cld.2007.02.002

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  22 in total

1.  A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis.

Authors:  Zobair M Younossi; Sandra Page; Nila Rafiq; Aybike Birerdinc; Maria Stepanova; Noreen Hossain; Arian Afendy; Zahra Younoszai; Zachary Goodman; Ancha Baranova
Journal:  Obes Surg       Date:  2011-04       Impact factor: 4.129

2.  Hepatic gene expression of Caucasian and African-American patients with obesity-related non-alcoholic fatty liver disease.

Authors:  Maria Stepanova; Noreen Hossain; Arian Afendy; Kellie Perry; Zachary D Goodman; Ancha Baranova; Zobair Younossi
Journal:  Obes Surg       Date:  2010-01-30       Impact factor: 4.129

Review 3.  Regulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome.

Authors:  Paul D Berk
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

4.  Evaluation of liver fat in the presence of iron with MRI using T2* correction: a clinical approach.

Authors:  Benjamin Henninger; Henninger Benjamin; Christian Kremser; Kremser Christian; Stefan Rauch; Rauch Stefan; Robert Eder; Eder Robert; Werner Judmaier; Judmaier Werner; Heinz Zoller; Zoller Heinz; Henrik Michaely; Michaely Henrik; Michael Schocke; Schocke Michael
Journal:  Eur Radiol       Date:  2013-01-19       Impact factor: 5.315

5.  Transient elastography improves detection of liver cirrhosis compared to routine screening tests.

Authors:  Thomas Göbel; Janine Schadewaldt-Tümmers; Lucas Greiner; Christopher Poremba; Dieter Häussinger; Andreas Erhardt
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

Review 6.  Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Authors:  Yoshihisa Takahashi; Toshio Fukusato
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

Review 7.  Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease.

Authors:  Nikolaos K Gatselis; George Ntaios; Konstantinos Makaritsis; George N Dalekos
Journal:  Clin Exp Med       Date:  2013-01-05       Impact factor: 3.984

8.  Early steatohepatitis in hyperlipidemic mice with endothelial-specific gain of TRPC3 function precedes changes in aortic atherosclerosis.

Authors:  Kathryn Smedlund; Prabhatachandra Dube; Guillermo Vazquez
Journal:  Physiol Genomics       Date:  2016-07-22       Impact factor: 3.107

9.  Development of nonalcoholic steatohepatitis in insulin-resistant liver-specific S503A carcinoembryonic antigen-related cell adhesion molecule 1 mutant mice.

Authors:  Sang Jun Lee; Garrett Heinrich; Larisa Fedorova; Qusai Y Al-Share; Kelly J Ledford; Mats A Fernstrom; Marcia F McInerney; Sandra K Erickson; Cara Gatto-Weis; Sonia M Najjar
Journal:  Gastroenterology       Date:  2008-08-20       Impact factor: 22.682

10.  High fat diet induced hepatic steatosis establishes a permissive microenvironment for colorectal metastases and promotes primary dysplasia in a murine model.

Authors:  Michael Nathan VanSaun; In Kyu Lee; Mary Kay Washington; Lynn Matrisian; David Lee Gorden
Journal:  Am J Pathol       Date:  2009-06-18       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.